Business
Danaher Reports Fourth Quarter and Full Year 2025 Results
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
About this update from Danaher Corporation
[{"type":"text","content":"WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.","length":310,"tagName":"p"},{"type":"text","content":"Key Fourth Quarter 2025 Results","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net earnings were $1.2 billion, or $1.66 per diluted common share.","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-GAAP adjusted diluted net earnings per common share grew 4.0% to $2.23.","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenues increased 4.5% year-over-year to $6.8 billion and non-GAAP core revenue increased 2.5% year-over-year.","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating cash flow was $2.1 billion and non-GAAP free cash flow was $1.8 billion.","length":82,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":334,"olType":false},{"type":"text","content":"Key Full Year 2025 Results","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net earnings were $3.6 billion, or $5.03 per diluted common share.","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-GAAP adjusted diluted net earnings per common share grew 4.5% to $7.80.","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenues increased 3.0% year-over-year to $24.6 billion and non-GAAP core revenue increased 2.0% year-over-year.","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating cash flow was $6.4 billion and non-GAAP free cash flow was $5.3 billion.","length":82,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":335,"olType":false},{"type":"text","content":"2025 Innovation Highlights","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Launched innovative new products and solutions, which strengthened Danaher's position as a trusted leader in life sciences and diagnostics.","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"Cytiva expanded its Xcellerex X-platform bioreactor with 500L and 2,000L formats, helping customers improve yields while reducing the time an...